Evidence map›Paper›PMID 27225012›Full record

ArticleJournal of clinical laboratory analysis2016

Comparison of Screening Dilution and Automated Reading for Antinuclear Antibody Detection on HEP2 Cells in the Monitoring of Connective Tissue Diseases.

Anne E Depincé-Berger, Amelie Moreau, Virginie Bossy, Christian Genin, Melanie Rinaudo, Stephane Paul

Abstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anne E Depincé-BergerLaboratoire d'Immunologie et d'Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, CHU de Saint-Etienne (France), Werfen Instrument Laboratory, France.
Amelie MoreauLaboratoire d'Immunologie et d'Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, CHU de Saint-Etienne (France), Werfen Instrument Laboratory, France.
Virginie BossyLaboratoire d'Immunologie et d'Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, CHU de Saint-Etienne (France), Werfen Instrument Laboratory, France.
Christian GeninLaboratoire d'Immunologie et d'Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, CHU de Saint-Etienne (France), Werfen Instrument Laboratory, France.
Melanie RinaudoLaboratoire d'Immunologie et d'Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, CHU de Saint-Etienne (France), Werfen Instrument Laboratory, France.
Stephane PaulLaboratoire d'Immunologie et d'Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, CHU de Saint-Etienne (France), Werfen Instrument Laboratory, France. stephane.paul@chu-st-etienne.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIndirect immunofluorescence plays a major role in the detection of antinuclear antibodies (ANAs) and follow-up of their titers in the context of connective tissue diseases. Given the numerous unfavorable features of the conventional manual reading of HEP2 slides (need of time and expert morphologists for the reading, lack of standardization, subjectivity of the interpretation), the biomedical industry has developed automated techniques of slide preparation and microscope reading.

methodsWe collected 49 sera beforehand analyzed by the conventional reading of slides. They were prepared again by QUANTA-Lyser(®) and reanalyzed in four different conditions: two dilutions of screening (1/40 and 1/80), two different systems of analysis, NOVA View(®) automated reading (INOVA Diagnostics), then confirmation by the operator, and conventional manual reading by two different qualified operators. The analysis was realized in blind of the first interpretation and clinical diagnosis. The sera were classified in four groups, on the basis of the results of the first analysis: negative sera (titer < 1/160; 11 patients), low positives (titer at 1/160; 18 patients), moderated positives (titers between 1/320 and 1/640; 10 patients), and strong positives (titers between 1/1,280 and 1/2,560; 10 patients).

resultsAmong the 49 patients, 13 presented a connective tissue disease including 4 systemic scleroderma (SS), 3 rheumatoid arthritis (RA), 2 Goujerot-Sjogren (GS), 2 systemic lupus erythematosus (SLE), 1 polymyositis (PM), 1 Raynaud's syndrome (RS), and 1 CREST syndrome. One patient presented both an SLE and an SS. Regarding the screening dilution, the 1/40 dilution is less specific than the 1/80 dilution for both the systems of analysis (5.6% vs. 16.7% for the manual reading, and 27.8% vs. 50% for the automated reading). It also generates statistically more false positives (P = 0.037 for the conventional analysis and P = 0.003 for the automated system). The automated NOVA View(®) reading of slides allows a gain in specificity for both dilutions, and also statistically less false positives (P = 0.002 at the 1/40 and P = 0.0006 at the 1/80), and detriment of the sensitivity at the highest dilution (84.6% vs. 92.3% with manual reading). Thus, according to our analysis of 49 sera, the automated NOVA View(®) system of reading of slides at the dilution 1/80 seems to be a successful condition for the detection of ANAs on HEP2 cells, close to the significance (P = 0.067).

conclusionThe automated NOVA View(®) reading of slides allows saving time, and an improvement in the standardization. Nevertheless, it requires a confirmation by a qualified operator, to interpret mixed patterns in particular.

Indexed as

Mass ScreeningAdolescentAdultAgedAged, 80 and overAlkaloidsAnalysis of VarianceAntibodies, AntinuclearCarcinomaCell Line, TumorChildConnective Tissue DiseasesElectronic Data ProcessingFemaleFollow-Up StudiesHumansAlkaloidsAntibodies, AntinuclearWilcox compoundANAConnective tissue diseaseconventional manual readingHEP2 cellsIIFNOVA View® automated reading of slides

Identifiers

PMID27225012
PMCPMC6806706

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.